麝香保心丸对急性心肌梗死经皮冠状动脉介入治疗术后患者心肌梗死面积及血液相关因子水平的影响  

Effect of Shenxiang Baoxin Pill on postoperative infarct area and blood-related factor of patients with acute myocardial infarction percutaneous coronary intervention

作　　者：张建刚[1] 戴士鹏[1] 刘华[1] 马增才[1] 刘娟[1] 徐泽升[1] ZHANG Jiangang;DAI Shipeng;LIU Hua;MA Zengcai;LIU Juan;XU Zesheng(Department of Cardiology,Cangzhou Central Hospital,Cangzhou,Hebei 061001)

机构地区：[1]河北省沧州市中心医院心血管内科,河北沧州061001

出　　处：《河北中医》2021年第4期596-599,共4页Hebei Journal of Traditional Chinese Medicine

基　　金：河北省沧州市科学技术局沧州市重点研发计划指导项目(编号:172302031)。

摘　　要：目的观察麝香保心丸对急性心肌梗死经皮冠状动脉介入治疗(PCI)术后患者临床症状、心肌梗死面积和血清脑钠肽(BNP)、生长分化因子-15(GDF-15)、超敏C反应蛋白(hs-CRP)水平及术后1年支架内再狭窄发生率的影响。方法将100例急性心肌梗死PCI术后患者按照随机数字表法分为2组,每组各50例。对照组术后24 h行标准化药物治疗,治疗组在对照组治疗基础上加麝香保心丸。2组均治疗1年,比较2组治疗前后胸痛、胸闷、气短、心悸评分,心肌梗死面积,血清BNP、GDF-15、hs-CRP水平,术后1年支架内再狭窄发生率。结果治疗后2组胸痛、胸闷、气短、心悸评分,心肌梗死面积,血清BNP、GDF-15、hs-CRP水平均较本组治疗前降低(P<0.05),且治疗组均低于对照组(P<0.05)。治疗组术后1年支架内再狭窄发生率为4.00%(2/50),对照组为8.00%(4/50),2组比较差异无统计学意义(P>0.05)。结论麝香保心丸治疗急性心肌梗死PCI术后患者临床疗效较好,可有效改善患者临床症状,抑制炎性反应,改善心肌功能,缩小心肌梗死面积。Objective To explore the effect of Shenxiang Baoxin pill on clinical symptom,infarct size,incidence of in-stent restenosis,serum brain natriuretic peptide(BNP),growth differentiation factor-15(GDF-15) and high-sensitivity c-reactive protein(hs-CRP) levels in patients with acute myocardial infarction(AMI) percutaneous coronary intervention(PCI).Methods Totally 100 AMI patients PCI were randomly assigned into control group and observation group,50 cases in each group.Patients in control group was treated with 24-h standardized medication,and patients observation group was treated with Shenxiang Baoxin pill on the basis of control group.Aiming to compare chest pain,chest distress,shortness of breath,palpitation,infarct size,serum BNP,GDF-15,hs-CRP,incidence of in-stent restenosis of postoperative one year.Results Compared with before treatment,chest pain,chest distress,shortness of breath,palpitation score,infarct size,serum BNP,GDF-15,and hs-CRP in both groups was lower after treatment(P < 0.05),which in treatment group was significantly decreased(P < 0.05).There was no significant difference in the incidence of in-stent restenosis of postoperative one year between treatment group and control group [4.00%(2/50) vs 8.00%(4/50),(P > 0.05),respectively].Conclusion For AMI patients PCI,Shenxiang Baoxin Pill has a good clinical effect,which can effectively improve clinical symptoms,inhibit inflammatory response,improve myocardial function,and reduce infarct size.

关 键 词：心肌梗死 经皮冠状动脉介入治疗 麝香保心丸 利钠肽 脑 生长分化因子15 C反应蛋白质 

分 类 号：R542.220.531[医药卫生—心血管疾病] R814.47[医药卫生—内科学]